The first few batches of covaxin were not approved for use in the human body due to their quality, said NK Aurora, head of the center’s covid antidote task force. On the other hand, covaxin Coroner Delta Plus has been claimed by India Biotech and Indian Council of Medical Research (ICMR) to be able to prevent the virus.
So far, the Center has given about 500 million doses of antidote to various states. About 50 million doses of covaxin. Recently, there has been a question about the lack of covaxin. In an interview with the media today, Aurora said, “The first few batches of covaxin did not get clearance due to poor quality. As a result, there is a shortage of covaxin production, ”he said.
The delta species was responsible for the second wave of corona in India. Later that species changed its character and became Delta Plus. However, there is still research on how harmful Delta Plus is to the question of infection. The first Delta Plus sample was found in India last April.So far, Delta Plus samples have been found in the bodies of only 60 people in India as the patients were quickly identified and brought under surveillance, the center said. Although many health experts fear that Delta Plus will spread to 70 countries, the species will be the main reason behind the third wave in the world in the coming days.
The Biotech Company of India claims that the effectiveness of the covaxin antidote is about 7.8 percent after the third application to the human body. In the case of delta species, its effectiveness was about 75.2 percent। At a time when the third wave of corona is hitting many countries, India Biotech today claimed that their covaxin antidote Delta Plus is capable of stopping the species. The study will be published soon in the journal BioR14, the agency said.They claim that studies have shown that the antibodies that are produced in the body as a result of giving that antidote are able to resist Delta Plus. The agency claims that at least 16 countries, including India, the Philippines, Iran, Mexico, and the United Arab Emirates, have received emergency clearance for the use of the antidote on an emergency basis.
ICMR is helping Biotech in India to produce covaxin. In return for that assistance, India Biotech will pay 5 per cent of the proceeds from the sale of their drugs to ICMR as royalty. Many have complained that in order to pay this royalty, citizens have to pay more for covaxin in private hospitals.”It looks like India Biotech OICMR is trying to make a profit by selling antidotes,” said Amul Nidhi, a spokesman for the Public Health Campaign.